Merck Says Winrevair Recommended for Reimbursement in Canada

By Stephen Nakrosis

Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension.

The agency recommended the reimbursement for patients using Winrevair, or sotatercept, in combination with standard pulmonary arterial hypertension therapy, the company said.

The next steps include the pan-Canadian Pharmaceutical Alliance engaging with Merck Canada to begin negotiations for Winrevair, which would move toward the treatment being publicly funded by participating drug plans in Canada.

Merck said sotatercept is the first activin signaling inhibitor therapy for pulmonary arterial hypertension in Canada. The company added it has been eight years since a new pharmacological therapy has been launched in Canada for pulmonary arterial hypertension.

Write to Stephen Nakrosis at [e-mail]

(END) Dow Jones Newswires

11-08-24 1532ET